All IndicationsInfectious DiseasePhase 3Phase 3Phase 3Phase 2Phase 2
🦠
HIV Infections
4
Companies
5
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
AGY.L
Allergy Therapeutics plc
Anti-HIV Immune Serum Globulin (Human)
GILD
Gilead Sciences, Inc.
didanosine, ddI (drug)
GILD
Gilead Sciences, Inc.
efavirenz (drug)
INCY
Incyte Corporation
INCB009471
CELG-RI
BRISTOL MYERS SQUIBB CO
Nevirapine
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| AGY.L Allergy Therapeutics plc | Anti-HIV Immune Serum Globulin (Human) | Phase 3 | — | — | — |
| GILD Gilead Sciences, Inc. | didanosine, ddI (drug) | Phase 3 | — | — | — |
| GILD Gilead Sciences, Inc. | efavirenz (drug) | Phase 3 | — | — | — |
| INCY Incyte Corporation | INCB009471 | Phase 2 | — | — | — |
| CELG-RI BRISTOL MYERS SQUIBB CO | Nevirapine | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
3
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.